CJC-1295 With DAC vs Without DAC: What the Research Shows

Meta description: CJC-1295 with DAC vs without DAC , half-life differences, pulsatile vs sustained GH release, and which form appears more in published research. Etched Research.

CJC-1295 with DAC and CJC-1295 without DAC are the same base GHRH analog sequence modified at the C-terminus in two different ways, producing dramatically different pharmacokinetic profiles: CJC-1295 without DAC has a circulating half-life of approximately 30 minutes and produces a pulsatile GH release pattern, while CJC-1295 with DAC binds serum albumin via its Drug Affinity Complex modification and extends the half-life to 6 to 8 days, producing sustained GH elevation. The distinction is mechanistically significant, and the two forms appear in different research contexts for different reasons.

Etched Research carries CJC-1295 without DAC as its standard GH-axis research compound. Understanding the pharmacological difference between the two forms is foundational to protocol design.

What the DAC Modification Does

The Drug Affinity Complex (DAC) modification appended to CJC-1295 with DAC consists of a lysine derivative coupled via a maleimide-functionalized linker to the C-terminus of the peptide. This lysine derivative contains a reactive thioester group that forms a covalent bond with the free thiol of cysteine-34 on circulating serum albumin.

The effect is a dramatic extension of circulating half-life. Native GHRH(1-29) is cleaved by dipeptidyl peptidase-IV (DPP-IV) within minutes of entering circulation, rendering it pharmacologically transient. CJC-1295 without DAC addresses this by substituting alanine at position 8 with a DPP-IV-resistant amino acid (the Ala8/Gln8 modification), extending half-life to approximately 30 minutes. Adding the DAC modification extends this further , by binding albumin, the peptide is effectively shielded from renal filtration and proteolytic degradation, achieving a half-life of 6 to 8 days in research models.

The albumin-bound form remains biologically active. It dissociates from albumin gradually, releasing functional peptide into circulation continuously over days. This is what produces the sustained GH elevation profile characteristic of CJC-1295 with DAC administration.

Molecular specifications for comparison:

| Parameter | CJC-1295 (No DAC) | CJC-1295 (With DAC) |

|—|—|—|

| Molecular weight | ~3367.97 g/mol | ~3647.28 g/mol |

| Half-life | ~30 minutes | 6-8 days |

| GH release pattern | Pulsatile | Sustained |

| Albumin binding | No | Yes (covalent via Cys-34) |

| DPP-IV resistance | Yes (Ala8 modification) | Yes |

Pulsatile vs Sustained GH Release: The Research Distinction

This is where the two forms diverge most significantly for research purposes.

Endogenous GH secretion is pulsatile. The hypothalamus releases GHRH in discrete bursts, triggering corresponding GH pulses from pituitary somatotrophs. These pulses occur approximately 8 to 12 times per 24-hour period in humans, with the largest pulses occurring during slow-wave sleep. Between pulses, GH levels are near zero. This pulsatile pattern is not incidental , it is functionally important. GH receptor downregulation occurs with continuous GH exposure, and the pulsatile pattern is required for sustained receptor sensitivity and downstream IGF-1 production.

CJC-1295 without DAC produces a GH pulse that models this endogenous pattern. Administered in research models, it triggers a discrete GH secretory event that returns to baseline within 1 to 2 hours. This mirrors physiological GHRH pulsatility and is the more biologically authentic model for studying GH axis dynamics.

CJC-1295 with DAC produces continuous, sustained GH elevation over days. This is not a physiological pattern. It is more analogous to exogenous GH administration than to endogenous GHRH signaling. The sustained elevation does produce measurable effects on GH-dependent outcomes like IGF-1, lean tissue, and fat metabolism in animal models , which is why the DAC form appears in studies focused on these downstream outcomes rather than GH axis dynamics per se.

The research question determines which form is appropriate. For studies investigating GH axis pulsatility, somatotroph response kinetics, or the role of pulsatile vs tonic GH secretion in specific biological outcomes, CJC-1295 without DAC is the appropriate tool. For studies where the research variable is a downstream outcome that requires sustained GH elevation to produce measurable effects in a practical experimental timeframe, CJC-1295 with DAC may be more useful.

Which Form Appears More in Published Literature and Why

A search of PubMed for CJC-1295 returns a substantially larger body of literature referencing the DAC form. This is partly a historical artifact: CJC-1295 with DAC was the formulation that received early clinical attention because the extended half-life made it attractive for proof-of-concept studies on GHRH analog biology in human subjects. The Teichman et al. (2006) paper in the Journal of Clinical Endocrinology and Metabolism, which characterized GH and IGF-1 responses to CJC-1295, used the DAC formulation and became a foundational citation in the field.

However, the research trend has shifted. As investigators moved from pharmacokinetic characterization toward mechanistic research on GH axis biology, the pulsatile form became more relevant. CJC-1295 without DAC (sometimes referred to in older literature as modified GRF(1-29) or Mod GRF 1-29) appears more frequently in studies examining GH pulse architecture, somatotroph regulation, and combined secretagogue protocols.

In the context of research combining CJC-1295 with Ipamorelin (a common protocol in the published and gray literature), CJC-1295 without DAC is overwhelmingly the form used. The rationale: Ipamorelin has a 2-hour half-life, and matching it with a similarly short-acting GHRH analog produces a synchronized dual-pathway pulse. Combining Ipamorelin with CJC-1295 with DAC creates a pharmacokinetic mismatch , the DAC form provides continuous background GHRH signaling while Ipamorelin provides intermittent GHS-R1a activation. Both protocols have appeared in the literature, but the mechanistic rationale favors the matched half-life approach.

Storage and Reconstitution Considerations

Both forms are supplied as lyophilized powder and reconstituted with bacteriostatic water. Storage requirements are identical: -20°C for lyophilized material, 4°C for reconstituted solution, with a 30-day shelf life post-reconstitution. The DAC modification does not meaningfully alter storage requirements.

One practical note: CJC-1295 with DAC is a larger molecule (MW ~3647 g/mol vs ~3368 g/mol for the no-DAC form) and may require slightly more agitation to achieve complete dissolution. Gentle swirling for 2 to 3 minutes is typically sufficient. Both forms dissolve readily in bacteriostatic water without requiring cosolvents.

Frequently Asked Questions

Q: What is the main difference between CJC-1295 with and without DAC?

A: The DAC (Drug Affinity Complex) modification causes CJC-1295 to bind serum albumin covalently, extending its half-life from approximately 30 minutes to 6 to 8 days. Without DAC, CJC-1295 produces a short pulsatile GH release. With DAC, it produces sustained GH elevation over days.

Q: Which form of CJC-1295 is more physiologically accurate?

A: CJC-1295 without DAC is more physiologically relevant for research on GH axis dynamics because it produces pulsatile GH release that mirrors endogenous GHRH biology. The DAC form produces continuous GH elevation, which does not reflect normal GH secretion patterns.

Q: What does CJC-1295 without DAC’s half-life affect in research design?

A: The approximately 30-minute half-life of CJC-1295 without DAC means GH elevation returns to baseline within 1 to 2 hours of administration. This makes it appropriate for time-resolved GH pulse studies and for combination protocols with similarly short-acting compounds like Ipamorelin.

Q: Why do researchers combine CJC-1295 without DAC with Ipamorelin specifically?

A: CJC-1295 without DAC and Ipamorelin have compatible pharmacokinetic profiles , both are short-acting, producing GH pulses that resolve within 2 to 3 hours. The combination activates GH release through two distinct receptor pathways (GHRH-R and GHS-R1a), producing synergistic GH release in published rodent models. The matched half-lives create a coordinated dual-pathway pulse.

Q: Which CJC-1295 form appears more in the published research literature?

A: Both forms appear in the published literature. CJC-1295 with DAC received more attention in early clinical pharmacokinetic research (including the Teichman et al. 2006 paper in JCEM). CJC-1295 without DAC appears more commonly in mechanistic research on GH pulsatility and in combined secretagogue protocols. The without-DAC form is generally preferred when pulsatile GH dynamics are the research variable of interest.

Researchers investigating GH axis pulsatility, GHRH receptor biology, or combined secretagogue protocols will find Etched Research’ CJC-1295 (without DAC) at etchedresearch.com, supplied as lyophilized powder with batch-specific COA documentation.

*All products mentioned are for research use only. Not for human consumption.*